Neumora Therapeutics (NMRA) Share-based Compensation (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Share-based Compensation of $7.4 million for Q1 2026, down 20.58% year-over-year from $9.3 million in Q1 2025, and little changed quarter-over-quarter from $7.4 million in Q4 2025.
Neumora Therapeutics (NMRA) Share-based Compensation (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Share-based Compensation history runs 5 years deep, the most recent figure standing at $7.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 20.58% year-over-year to $7.4 million; the TTM figure through Mar 2026 stood at $28.0 million (down 61.19% YoY), while the FY2025 annual figure was $35.0 million, down 12.48% from the prior year.
- Share-based Compensation for Q1 2026 stood at $7.4 million, roughly flat from $7.4 million in the prior quarter.
- The five-year high for Share-based Compensation was $40.0 million in Q4 2024, with the low at $2.1 million in Q3 2022.
- The 5-year median for Share-based Compensation is $7.3 million (2024), against an average of $8.8 million.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation jumped 560.88% in 2024, then tumbled 81.48% in 2025.
- Neumora Therapeutics' Share-based Compensation stood at $2.8 million in 2022, then surged by 116.73% to $6.1 million in 2023, then surged by 560.88% to $40.0 million in 2024, then sank by 81.48% to $7.4 million in 2025, then dropped by 0.03% to $7.4 million in 2026.
- Business Quant data shows NMRA's Share-based Compensation at $7.4 million in Q1 2026, $7.4 million in Q4 2025, and $6.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 7.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.41 Mn |
| Mar 31, 2026 | 7.41 Mn |
| Dec 31, 2025 | 7.41 Mn |
| Dec 31, 2025 | 7.41 Mn |
| Sep 30, 2025 | 5.98 Mn |
| Sep 30, 2025 | 5.98 Mn |
| Jun 30, 2025 | 7.17 Mn |
| Jun 30, 2025 | 7.17 Mn |
| Mar 31, 2025 | 9.32 Mn |
| Mar 31, 2025 | 9.32 Mn |
| Dec 31, 2024 | 39.99 Mn |
| Dec 31, 2024 | 39.99 Mn |
| Sep 30, 2024 | 9.95 Mn |
| Sep 30, 2024 | 9.95 Mn |
| Jun 30, 2024 | 12.77 Mn |
| Jun 30, 2024 | 12.77 Mn |
| Mar 31, 2024 | 7.37 Mn |
| Mar 31, 2024 | 7.37 Mn |
| Dec 31, 2023 | 6.05 Mn |
| Dec 31, 2023 | 6.05 Mn |